 |
JOURNAL TOOLS |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Permissions |
| Cite this article as |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS
Minerva Cardioangiologica 2015 June;63(3):205-16
Copyright © 2015 EDIZIONI MINERVA MEDICA
language: English
Transcatheter Aortic Valve Implantation Experience with SAPIEN 3
Ohno Y. 1, 2, Tamburino C. 1, 3, Barbanti M. 1 ✉
1 Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2 Department of Cardiology, University of Tokai School of Medicine, Isehara, Japan; 3 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy
Based on randomized trials with first generation devices, transcatheter aortic valve replacement (TAVI) has been included into the treatment strategy for high-risk and inoperable patients with severe aortic stenosis. Procedural complications remain a concern with TAVI, including stroke, vascular complications, paravalvular leak (PVL) and conduction disturbances. Addressing these limitations will support TAVI use in lower risk populations. This review discussed features and most recent clinical evidence of the new balloon-expandable THV (SAPIEN 3, Edwards Lifescience, Irvine, CA, USA).